Idiopathic Pulmonary Fibrosis Market: Advancing Therapies and Changing Treatment Dynamics

Idiopathic Pulmonary Fibrosis Market Overview

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive interstitial lung disorder characterized by persistent scarring of the lungs. As fibrosis advances, lung function progressively declines, making breathing increasingly difficult and significantly affecting patients’ quality of life. The idiopathic pulmonary fibrosis treatment market is undergoing notable transformation as established antifibrotic medicines continue to slow disease progression while newer therapies are being developed to address remaining unmet medical needs. According to DelveInsight, the overall IPF market across the 7MM was valued at approximately USD 3.3 billion in 2023 and is expected to expand during the forecast period through 2036. The assessment covers the United States, EU4, the United Kingdom, and Japan.

Idiopathic Pulmonary Fibrosis Disease Burden and Epidemiology

IPF predominantly affects older adults and is associated with a gradual decline in respiratory capacity. According to DelveInsight’s epidemiological assessment, approximately 300,000 diagnosed prevalent cases were reported across the 7MM in 2025. The United States represented the largest portion of this patient population, accounting for nearly 125,000 diagnosed prevalent cases.

Within European markets, the United Kingdom had approximately 37,500 diagnosed cases, while France accounted for around 12,300 cases. Increasing life expectancy, greater awareness of respiratory disorders, improvements in diagnostic approaches, and the presence of age-related comorbidities are among the factors influencing the disease burden.

The age distribution of IPF also plays an important role in shaping treatment requirements. Earlier epidemiological assessments indicated that the highest number of cases occurred among individuals aged 60–79 years, followed by those aged 80 years and above. Men represented a greater proportion of diagnosed prevalent cases than women across the 7MM. These demographic characteristics are expected to continue affecting diagnosis patterns, healthcare utilization, and demand for effective disease-management options.

Idiopathic Pulmonary Fibrosis Current Treatment Landscape

Treatment for IPF primarily aims to slow pulmonary function decline, preserve respiratory capacity, manage symptoms, and reduce the impact of disease-related complications. Nintedanib and pirfenidone have traditionally remained key antifibrotic treatments, offering the ability to slow disease progression rather than reverse existing pulmonary fibrosis. Despite their clinical utility, treatment-related adverse events, including gastrointestinal complications and tolerability concerns, can influence treatment continuation.

The therapeutic environment has recently expanded with the availability of JASCAYD (nerandomilast). DelveInsight reports that the US FDA approved JASCAYD in October 2025, marking a significant addition to the IPF treatment landscape after more than a decade without a new approved therapy for the disease. The emergence of therapies based on alternative biological mechanisms demonstrates the industry's growing interest in expanding beyond conventional antifibrotic approaches.

Idiopathic Pulmonary Fibrosis United States Market Dynamics

The United States remains a major contributor to the global IPF landscape because of its considerable patient population, established healthcare infrastructure, advanced diagnostic capabilities, and access to innovative therapies. The US idiopathic pulmonary fibrosis treatment market is anticipated to remain an important component of the overall 7MM market during the forecast period.

Advances in disease recognition and diagnostic technologies may support the identification of patients at earlier stages. Clinical evaluation can involve pulmonary function tests, high-resolution computed tomography, laboratory assessments to exclude alternative causes, and, in selected circumstances, lung biopsy. More accurate diagnosis can help physicians initiate appropriate disease management and treatment strategies at an earlier stage.

Market development in the United States is also influenced by reimbursement conditions, pricing structures, regulatory decisions, healthcare policies, and the introduction of innovative therapies. Changes across these areas may affect patient access, prescribing patterns, and the commercial performance of both established and emerging products.

Idiopathic Pulmonary Fibrosis European Market Outlook

Europe remains an important region within the global IPF treatment landscape, with Germany, France, Italy, Spain, and the United Kingdom contributing to the regional market. The Europe idiopathic pulmonary fibrosis treatment market accounted for a substantial portion of the overall 7MM market. DelveInsight estimated that the combined EU4 and UK market was nearly USD 702 million in 2023, representing approximately 21% of the total 7MM market.

Germany represented around USD 183 million of the regional market, followed by the United Kingdom at approximately USD 141 million and France at nearly USD 140 million. Differences in national healthcare systems, reimbursement mechanisms, treatment guidelines, physician preferences, and patient access can contribute to variations in therapy utilization across European countries.

Treatment rates may also differ according to disease severity and diagnosis patterns. As healthcare systems continue evaluating innovative therapies through pricing and health technology assessment frameworks, these factors are expected to influence the adoption and commercialization of emerging IPF treatments.

Idiopathic Pulmonary Fibrosis Emerging Therapies and Pipeline Development

The future of IPF treatment is increasingly linked to research into alternative mechanisms involved in fibrosis and progressive lung injury. Developers are exploring therapies designed to address disease progression, treatment tolerability, and the limitations associated with currently available antifibrotic medicines.

DelveInsight highlights several investigational and emerging therapies of interest, including pamrevlumab, inhaled treprostinil, PLN-74809, BI 1015550, C21, and BMS-986278. Deupirfenidone (LYT-100) has also remained an area of development interest. PureTech reported a successful End-of-Phase II meeting with the FDA in December 2025 and outlined plans for the Phase III SURPASS-IPF study.

At the same time, the broader fibrotic diseases treatment market is attracting increased research into fibrosis-related molecular pathways, inflammatory mechanisms, extracellular matrix remodeling, and progressive tissue damage. These scientific advances could support the development of therapies capable of complementing existing treatment strategies or providing alternative approaches for patients with limited treatment options.

Idiopathic Pulmonary Fibrosis Competitive Landscape and Market Expansion

The competitive environment includes established pharmaceutical organizations as well as biotechnology companies pursuing innovative approaches to IPF management. Companies such as FibroGen, United Therapeutics, Pliant Therapeutics, Boehringer Ingelheim, Vicore Pharma, and Bristol Myers Squibb are among the participants identified by DelveInsight in the evolving treatment landscape.

Clinical trial progress, regulatory developments, strategic collaborations, licensing activities, and continued investment in respiratory research are expected to influence the competitive environment through the forecast period. The success of pipeline candidates will depend on clinical efficacy, safety, tolerability, regulatory outcomes, and their ability to address gaps associated with currently available treatments.

The IPF landscape also connects with the wider idiopathic interstitial pneumonias market, where developments in biomarkers, imaging technologies, disease classification, and clinical research may contribute to improved differentiation and management of fibrotic lung diseases. Research presented at the American Thoracic Society 2024 conference included work related to biomarker development, distinguishing fibrotic hypersensitivity pneumonitis from IPF, circulating proteomic analysis, and methods for predicting disease characteristics and severity.

Idiopathic Pulmonary Fibrosis Market Future Outlook

The IPF treatment landscape is continuing to evolve as researchers and pharmaceutical developers seek solutions to persistent therapeutic challenges. Increasing disease awareness, improvements in diagnosis, an aging population, and the development of therapies based on novel mechanisms are expected to influence the market over the coming years.

Regional differences in disease prevalence, healthcare infrastructure, reimbursement policies, treatment access, and regulatory frameworks will continue to shape market development across the 7MM. Meanwhile, ongoing clinical research and pipeline advancement may introduce additional therapeutic choices for patients and healthcare professionals.

Latest Reports by DelveInsight:

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Abhishek kumar

Email: abhishek@delveinsight.com

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com

Search This Blog

Delveinsight Report